Amyloidosis Treatment Market By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care, Surgery), By End-use (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Amyloidosis Treatment Market was valued at USD 3.3 billion in 2023 and will surpass USD 5.6 billion by 2030; growing at a CAGR of 8.1% during 2024 - 2030.

The amyloidosis treatment market is focused on addressing the challenges posed by amyloidosis, a group of diseases where abnormal proteins (amyloids) build up in organs and tissues, leading to a variety of symptoms. Amyloidosis is a rare and often overlooked condition, making its treatment a significant challenge for healthcare systems worldwide. The market is characterized by a range of therapeutic options, including chemotherapy, immunosuppressive drugs, and novel treatments designed to target amyloid deposits more effectively. As awareness grows and diagnostic methods improve, the market for amyloidosis treatment is projected to grow steadily over the coming years. Advances in biologics, immunotherapy, and personalized medicine are shaping the future of this market, offering hope for patients with limited treatment options.

Chemotherapy Remains the Largest Treatment Option

Among the various treatment modalities for amyloidosis, chemotherapy remains the largest subsegment due to its long-standing role in managing the condition. Chemotherapy drugs are often used in cases of systemic amyloidosis, particularly in patients with AL (light chain) amyloidosis, where abnormal plasma cells produce light chains that form amyloid deposits. Chemotherapy, often used in conjunction with other treatments, works by reducing the number of these plasma cells, thereby halting the production of amyloid proteins. The primary chemotherapy agents used in treating amyloidosis include melphalan and cyclophosphamide, which have proven effective in improving patient outcomes. Although chemotherapy can lead to adverse side effects, its ability to manage the condition and prevent further organ damage ensures its continued dominance in the treatment landscape. Ongoing research into combining chemotherapy with newer treatment options, such as immunotherapy and targeted therapies, holds promise for enhancing treatment efficacy and reducing side effects.

Immunosuppressive Drugs Show Promising Growth

In terms of the fastest-growing treatment options, immunosuppressive drugs are gaining traction due to their ability to target the underlying immune response that contributes to the development of amyloidosis. These drugs work by suppressing the production of amyloid-forming proteins and inhibiting the immune system's activity, thereby reducing amyloid deposition. Immunosuppressive drugs, such as corticosteroids, are frequently used in conjunction with chemotherapy or stem cell transplants, particularly for patients with autoimmune-related forms of amyloidosis. The rising adoption of biologic therapies, which include monoclonal antibodies and other advanced immunosuppressive treatments, is expected to fuel the rapid growth of this subsegment. Immunosuppressive therapies are especially effective in reducing inflammation, managing symptoms, and improving the overall quality of life for amyloidosis patients. As the treatment landscape evolves, the integration of immunosuppressive drugs with other modalities is likely to result in more personalized and effective treatment regimens for patients.

Hospitals & Clinics Lead the End-Use Segment

In terms of end-use, hospitals and clinics are the largest segment in the amyloidosis treatment market. These healthcare settings are equipped with advanced diagnostic tools and medical expertise, making them the primary venue for diagnosing and treating amyloidosis. Hospitals and clinics are central to administering chemotherapy, immunosuppressive therapies, and performing complex procedures such as stem cell transplants. Furthermore, these institutions provide comprehensive patient care, offering support services like counseling and symptom management, which are crucial for patients coping with the chronic and often debilitating nature of amyloidosis. The market is expected to continue growing in this segment as hospitals and clinics expand their capabilities in treating rare diseases, with more specialized treatment centers emerging to address the unique needs of amyloidosis patients.

North America Leads the Amyloidosis Treatment Market

North America is the largest region in the amyloidosis treatment market, driven by a combination of factors, including a well-established healthcare infrastructure, advanced diagnostic technologies, and high awareness of rare diseases like amyloidosis. The region's healthcare system is equipped to handle complex cases of amyloidosis, offering a wide range of treatment options, including cutting-edge therapies and clinical trials. In addition, the increasing prevalence of amyloidosis in North America, particularly in aging populations, is fueling market growth. The United States, in particular, is home to numerous leading research institutions and pharmaceutical companies focused on amyloidosis treatment. As the demand for effective therapies grows, North America remains at the forefront of developing new treatment options, making it a key player in the global amyloidosis treatment market.

Competitive Landscape: Key Players in the Market

The amyloidosis treatment market is competitive, with several key players leading the charge in developing innovative therapies. Notable companies include Pfizer, Celgene Corporation, Johnson & Johnson, Amgen, and Bristol-Myers Squibb. These companies are focusing on expanding their portfolios with new biologics, targeted therapies, and combination treatments to improve patient outcomes and reduce side effects. Research and development in the field of amyloidosis is gaining momentum, with a strong emphasis on personalized medicine and immunotherapy. Collaboration between pharmaceutical companies, healthcare providers, and academic institutions is driving progress in the development of more effective treatments. With the rising demand for effective amyloidosis therapies, competition is expected to intensify, leading to the introduction of novel treatment options in the market.

Recent Developments:

• In November 2023, Alnylam Pharmaceuticals received FDA approval for its novel RNAi therapeutic aimed at treating ATTR amyloidosis, marking a major milestone in amyloidosis care.
• In October 2023, Amgen announced the launch of a new monoclonal antibody specifically targeting amyloid deposits in AL amyloidosis, with clinical trials showing promising results for heart and kidney functions.
• In September 2023, Pfizer reported positive Phase 3 trial results for its gene therapy targeting hereditary amyloidosis, anticipating regulatory submission in early 2024.
• In August 2023, Prothena Corporation announced its partnership with Bristol Myers Squibb to accelerate the development of a new treatment for systemic amyloidosis, with expected clinical trial results by mid-2024.
• In July 2023, the European Medicines Agency (EMA) granted orphan drug status to a new drug aimed at treating amyloid deposits in the liver, focusing on hereditary ATTR amyloidosis.

List of Leading Companies:

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• GSK plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Sanofi
• Alnylam Pharmaceuticals, Inc.

Report Scope: